The India Primary Hyperoxaluria (PH) Therapeutics market was valued at $XX Bn in 2022 and is estimated to expand at a CAGR of 7.8% from 2022 to 2030 and will reach $XX Bn in 2030. One of the main reasons propelling the growth of this market is government initiatives, aging population. The market is segmented by diagnostic method, by treatment, and by type. Some key players in this market are Biocon Limited, Sun Pharmaceutical Industries Limited, Lupin Limited, Dr. Reddy's Laboratories, Glenmark Pharmaceuticals, Zydus Cadila, Cipla, Alnylam Pharmaceuticals, among others.
The India Primary Hyperoxaluria (PH) Therapeutics market was valued at $XX Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.8% from 2022 to 2030 and will reach $XX Bn in 2030. An uncommon hereditary condition called primary hyperoxaluria (PH) causes the body to produce too much oxalate, which can cause kidney stones, chronic kidney disease, and other problems. India primary hyperoxaluria (PH) therapeutics market is currently in its nascent stages, with no approved treatments currently available.
Market Growth Drivers
The prevalence of PH in India is on the rise, leading to a growing demand for effective treatments. As awareness about the disease increases, more patients are likely to seek treatment, which is expected to drive market growth. The development of advanced drug delivery systems and innovative therapies, such as RNAi and enzyme replacement therapies, is driving the growth of the PH therapeutics market in India. These novel therapies offer improved efficacy and safety profiles, leading to increased adoption by healthcare providers and patients. The Indian government is actively promoting the development of the healthcare sector, including rare disease treatments. Various initiatives, such as the National Health Policy and the National Rare Disease Policy, are expected to boost the PH therapeutics market by providing a supportive regulatory environment and funding for research and development. With rising disposable income and an aging population, healthcare expenditure in India is expected to increase significantly in the coming years. This is likely to boost demand for PH therapeutics and drive market growth. Patient advocacy groups are playing an increasingly important role in raising awareness about rare diseases such as PH. This is expected to drive demand for effective treatments and increase funding for research and development, leading to growth in the PH therapeutics market.
Market Restraints
The development of novel therapies for rare diseases such as PH is a costly and time-consuming process, leading to high treatment costs. As a result, many patients may not be able to afford these treatments, leading to limited market growth. PH is a rare disease, and many patients may not be aware that they have the condition. In addition, diagnosis can be challenging, leading to delays in treatment and increased disease burden. PH is a rare disease, and the patient pool in India is relatively small. This can limit the market potential for PH therapeutics, leading to limited investment in research and development. The regulatory environment for rare disease treatments in India is still evolving, leading to uncertainty for drug developers. This can make it challenging to obtain regulatory approval for new therapies and can slow down market growth. The management of rare diseases such as PH requires specialized healthcare facilities and expertise, which may not be available in all parts of India. This can limit patient access to effective treatments and can hamper market growth.
Key Players
In India, the healthcare policy and regulatory framework for rare disease treatments, including primary hyperoxaluria (PH), is still evolving. The National Health Policy 2017, released by the Indian government, recognizes the need for an integrated approach to rare disease management, including the development of new treatments and therapies. The policy aims to improve access to healthcare services, including for rare diseases, and to promote research and development in the healthcare sector.
In 2017, the Indian government also released the National Rare Disease Policy, which aims to improve the diagnosis and management of rare diseases in the country. The policy provides a framework for the development of rare disease treatments and therapies, including incentives for drug developers and funding for research and development.
The Central Drugs Standard Control Organization (CDSCO) is responsible for regulating the approval and marketing of pharmaceuticals in India. The CDSCO has established specific guidelines for the development and approval of drugs for rare diseases, including PH. In addition, the Indian government has established the Department of Biotechnology (DBT) and the Indian Council of Medical Research (ICMR) to support research and development in the healthcare sector. These organizations provide funding for research and development projects, including for rare disease treatments.
The reimbursement scenario for primary hyperoxaluria (PH) therapeutics in India is currently limited. The cost of treatment for PH can be high, and many patients may not be able to afford the treatments without financial support. In addition, there are currently no specific reimbursement policies or schemes for rare disease treatments in India. However, the Indian government has recently taken steps to address the issue of high treatment costs for rare diseases. For example, in 2018, the government launched the Ayushman Bharat - Pradhan Mantri Jan Arogya Yojana, which is a national health insurance scheme that provides coverage for hospitalization expenses for over 100 Mn families in India. The scheme includes coverage for treatments for rare diseases, including PH, although the specific details of the coverage may vary depending on the state and hospital.
In addition, some pharmaceutical companies that manufacture PH therapeutics have established patient assistance programs to help patients with the costs of treatment. These programs may provide financial assistance or discounts on the cost of medications, although eligibility criteria and availability may vary depending on the company and product.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
By Diagnostic method
By Treatment
By Type
Insights10 will provide you with the reports within 10 key parameters which are:
Based on our many years of experience, we believe that these are the parameters that are critical to decision-making for business stakeholders. Our focused approach to developing reports focused on 10 key parameters, enabled us to arrive at the name “Insights10”.
Stage I: Market Data Collection
Primary Interviews: We have developed a network of experts, freelancers, and researchers across countries through which we engage with local experts to gather key data points and assumptions about each market. We also engage regularly with some of the best market research agencies such as Atheneum, GuidePoint, GLG, etc. to conduct surveys and interviews, and build intelligence. We have language translators as a part of our team, who between them can cover 30+ languages allowing us to extract better local insights.
Secondary Data Collection: We have developed strong expertise and experience in secondary data collection methods for developing unique data sets and research material. We gather data from multiple reliable sources to maintain a high level of accuracy and consistency. The market data is analyzed and forecasted using appropriate statistical and coherent models. The report offers an overall analysis of the market size, growth, and market share as well as a segment-level analysis of the specific market. Our report includes precise, to-the-point information related to the overall market, competition, growth drivers, challenges, regulatory updates, and competition.
Data Sources: We have access to multiple highly reliable free and subscription data sources. We have many years of experience to understand which sources are more dependable for what and which to prefer for the reliable and latest information. The key sources of information include the following, but are not limited to:
Stage II: Market Data Analysis and Statistical Model
Market Trends: We generally look at macro parameters and micro indicators. The macro parameters include changes in government policies, demand and supply of the market, government intervention programs, and major market share. The micro indicators are GDP growth, market size, market volume, etc. We also understand nuances specific to each country like the US, Canada, India, Germany, etc., and have worked across 60+ countries and hence not only understand global trends but how these differ by country, how payment models, market structure, cultural parameters, etc. differ in each country.
Market Sizing and Analysis: Our expert data analytics team has created various market forecast models by employing the top-down approach i.e. starting with the large overall market and segmenting different areas and the bottom-up approach i.e. starting with population and epidemiology and rolling up based on spend, etc., estimating the size of the market, and distributing among the geographic and/or product segments.
The top-down approach is mainly used for new product forecasting and the bottom-up approach is used for demand estimation of any product for different countries summed up to form the total market. We are able to round off insights and build stronger forecasts because we always do both these methods and triangulate the final numbers.
The study on the market covers the analysis of the leading geographies such as Asia-Pacific, Africa, Europe, Middle East, North America, and Latin America for the period of 2022 to 2030. The qualitative analysis covers the industry landscape and trends, market opportunities, competitive landscape, and policy and regulatory scenario, and the quantitative analysis covers different market estimates and forecasts.
Data Triangulation & Validation:
Data triangulation of various sources and results of the research are carried out by benchmarking with reliable sources such as industry statistics, statistical databases, and company-level averages, etc.
We make sure to finalize the numbers in alignment with the market research. Firstly, our internal experts ensure thorough validation and checking to ensure accurate and precise analysis and then validation is also done using a multiple-data analysis model. Two-level validation is done and entails the finalization of the report scope and the way of representation pattern.
Stage III: Interpretation and Presentation
Analysis & Interpretation: The information gathered is then analyzed and synthesized. The second series of interviews are done if necessary to check and validate. The future opportunities are analyzed by understanding product commercialization and many other factors. It also comprises the analysis of data discrepancies observed across various data sources. Information procured from secondary and primary results is then, interpreted by considering the following parameters: (a partial list)
Insights: Our reports deliver actionable insights backed with supporting facts and figures to assist you in achieving exemplary growth. Our in-depth analyses are interspersed with relevant insights and statistics to offer an executive-level view of a given market. The description helps in correlating many minor factors affecting the market and their impact on the different segments within the market.
Data curated from the analysis and interpretation are drawn to portray all in one consolidated report.
Presentation & Reporting: The market research report is presented in different forms such as charts by using a scientific approach for easy understanding. Historic, current, and future analysis is provided for each market in terms of both value and volume. The size of the market is interpreted in the US Dollar value and the respective unit, based on the product, for volume consumption.
The foreign exchange rates are calculated on the respective dates and for the respective regions covered in the study.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
This report addresses
Need more?